.jpg)
STAT Plus: Watch: CEO Daniel O’Day says Gilead is in a ‘sweet spot.’ What’s next?
What’s Gilead going to buy? That’s the single, persistent question Daniel O’Day has faced in…
Category: STAT Summit
STAT Plus: Watch: Dr. James Wilson, a scientific pioneer, on the future of gene therapy
Dr. James Wilson is a pioneer in gene therapy. That does not mean he is…
STAT Plus: Watch: Top Biogen scientist explains why he’s confident in company’s drug for Alzheimer’s
Does the Alzheimer’s drug aducanumab work? That was the central issue during an interview of…
STAT Plus: This invite-only club is grooming new biotech CEOs — and helping make them less lonely, too
Steve Woit runs an exclusive, confidential, invite-only club for biotech CEOs — but it’s not…
Listen: Warren’s awkward home front, the ethics of treating dwarfism, and the sound of STAT Summit
Can Sen. Elizabeth Warren ever go home again? Is it ethical to make little people…
STAT Plus: Watch: The state of biotech at time of innovation — and high prices
CAMBRIDGE, Mass. — We live in an age of miracles, but they come at a…
Biogen’s top scientist nearly dares FDA not to approve Alzheimer’s drug
Biogen’s top scientist offered unflinching support Thursday for the efficacy of the company’s controversial Alzheimer’s…
STAT Plus: A bold prediction: Machine learning will yield new drug candidates within three years
CAMBRIDGE, Mass. — An explosion of biological data will lead to the first drug candidates…
STAT Plus: ‘The industry has earned it’: Three CEOs own up to biopharma’s bad reputation
CAMBRIDGE, Mass. — Biopharma’s reputation is, objectively speaking, the worst. And on Thursday, several biotech…
STAT Plus: Gene therapy pioneer says the field is behind — and that delivery technology is ‘embarrassing’
CAMBRIDGE, Mass. — Gene therapy pioneer Dr. James Wilson is disappointed by the progress in…
Gilead CEO Daniel O’Day says company is in an ‘acquisitive mode’
CAMBRIDGE, Mass. — Daniel O’Day, in his eight months on the job as CEO of…